Alzheimer's Disease: Treatment

Cholinesterase inhibitors—donepezil, rivastigmine, and galantamine—are first-line treatments for mild to moderate Alzheimer's disease. These drugs inhibit acetylcholinesterase in the central nervous system, enhancing cholinergic transmission to compensate for the loss of cholinergic neurons characteristic of the disease. They provide short-term cognitive benefits and help manage symptoms.

Cholinesterase inhibitors block the enzyme acetylcholinesterase, which normally breaks down acetylcholine. By inhibiting this enzyme, these drugs increase acetylcholine levels in the brain, enhancing cholinergic transmission. This compensates for the degeneration of cholinergic neurons in Alzheimer's disease and temporarily improves cognitive function.

Common adverse effects of cholinesterase inhibitors include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and anorexia. Patients may also experience tremors, bradycardia, and muscle cramps. These side effects are generally manageable and often diminish with continued use or dose adjustment.

Memantine is an NMDA receptor antagonist used in moderate to severe Alzheimer's disease. It limits calcium ion influx into neurons, preventing neuronal damage caused by excessive glutamate excitotoxicity. Memantine is often combined with cholinesterase inhibitors due to its different mechanism of action and potential neuroprotective effects.

Behavioral and psychiatric symptoms in dementia are managed using SSRIs or atypical antipsychotics alongside cholinesterase inhibitors and memantine. These antidepressant drugs tricyclics SSRIs and SNRIs help address mood and behavioral disturbances while cognitive medications address memory and thinking problems, providing comprehensive symptom management.

No, Alzheimer's disease remains incurable despite available treatments. Current pharmacotherapy is symptomatic and palliative, managing cognitive and behavioral symptoms while delaying disease progression. These drugs improve quality of life but do not alter the underlying neurodegenerative process or reverse amyloid plaques and tau pathology.

NMDA receptor antagonists like memantine prevent excessive calcium influx triggered by glutamate overstimulation, protecting neurons from excitotoxic damage. These drugs are used in moderate to severe stages and offer neuroprotective benefits distinct from cholinesterase inhibitors, making them valuable adjuncts in multi-pronged Alzheimer's treatment strategies.